RATIONALE: Ziprasidone is an atypical antipsychotic recommended to be administered twice daily. OBJECTIVES: The purpose of this study was to investigate whether occupancy of the dopamine D2/3 receptors by ziprasidone is maintained across a day employing a within subject design. METHODS: Positron emission tomography (PET) scans with [(11)C]-raclopride were performed in 12 patients with schizophrenia while treated with ziprasidone 60 mg twice daily. Each patient completed [(11)C]-raclopride PET scans at 5, 13 and 23 h after the last dose of ziprasidone. Dopamine D2/3 receptor occupancy was estimated with reference to binding potential data of 44 age- and sex-matched control subjects in the caudate, putamen and ventral striatum. RESULTS: Eleven scans were available at each time point, and the mean occupancies at 5-, 13- and 23-h scans were 66, 39 and 2 % in the putamen; 62, 35 and -6 % in the caudate; and 68, 47 and 11 % in the ventral striatum, respectively. The time-course of receptor occupancy across the regions indicated an occupancy half-life of 8.3 h. The serum level of ziprasidone associated with 50 % D2/3 receptors occupancy was estimated to be 204 nmol/L (84 ng/ml). Prolactin levels were highest at 5-h post-dose and none showed hyperprolactinemia at 23-h scans. CONCLUSIONS: The absence of ziprasidone striatal D2/3 receptor binding 23 h after taking 60 mg under steady-state conditions is consistent with its peripheral half-life. The results support our earlier report that ziprasidone 60 mg administered twice daily appears to be the minimal dose expected to achieve therapeutic central dopamine D2/3 receptor occupancy (i.e. 60 %). CLINICAL TRIALS REGISTRATION: 24-Hour Time Course of Striatal Dopamine D2 Receptor Occupancy of Ziprasidone: A PET Study, www.clinicaltrials.gov/ct2/show/NCT00818298 , NCT00818298.
RATIONALE: Ziprasidone is an atypical antipsychotic recommended to be administered twice daily. OBJECTIVES: The purpose of this study was to investigate whether occupancy of the dopamine D2/3 receptors by ziprasidone is maintained across a day employing a within subject design. METHODS: Positron emission tomography (PET) scans with [(11)C]-raclopride were performed in 12 patients with schizophrenia while treated with ziprasidone 60 mg twice daily. Each patient completed [(11)C]-raclopride PET scans at 5, 13 and 23 h after the last dose of ziprasidone. Dopamine D2/3 receptor occupancy was estimated with reference to binding potential data of 44 age- and sex-matched control subjects in the caudate, putamen and ventral striatum. RESULTS: Eleven scans were available at each time point, and the mean occupancies at 5-, 13- and 23-h scans were 66, 39 and 2 % in the putamen; 62, 35 and -6 % in the caudate; and 68, 47 and 11 % in the ventral striatum, respectively. The time-course of receptor occupancy across the regions indicated an occupancy half-life of 8.3 h. The serum level of ziprasidone associated with 50 % D2/3 receptors occupancy was estimated to be 204 nmol/L (84 ng/ml). Prolactin levels were highest at 5-h post-dose and none showed hyperprolactinemia at 23-h scans. CONCLUSIONS: The absence of ziprasidone striatal D2/3 receptor binding 23 h after taking 60 mg under steady-state conditions is consistent with its peripheral half-life. The results support our earlier report that ziprasidone 60 mg administered twice daily appears to be the minimal dose expected to achieve therapeutic central dopamine D2/3 receptor occupancy (i.e. 60 %). CLINICAL TRIALS REGISTRATION: 24-Hour Time Course of Striatal Dopamine D2 Receptor Occupancy of Ziprasidone: A PET Study, www.clinicaltrials.gov/ct2/show/NCT00818298 , NCT00818298.
Authors: Alette M Wessels; Robert R Bies; Bruce G Pollock; Lon S Schneider; Jeffrey A Lieberman; Scott Stroup; Claire H Li; Kim Coley; Margaret M Kirshner; Stephen R Marder Journal: J Clin Pharmacol Date: 2011-01-05 Impact factor: 3.126
Authors: Robert B Innis; Vincent J Cunningham; Jacques Delforge; Masahiro Fujita; Albert Gjedde; Roger N Gunn; James Holden; Sylvain Houle; Sung-Cheng Huang; Masanori Ichise; Hidehiro Iida; Hiroshi Ito; Yuichi Kimura; Robert A Koeppe; Gitte M Knudsen; Juhani Knuuti; Adriaan A Lammertsma; Marc Laruelle; Jean Logan; Ralph Paul Maguire; Mark A Mintun; Evan D Morris; Ramin Parsey; Julie C Price; Mark Slifstein; Vesna Sossi; Tetsuya Suhara; John R Votaw; Dean F Wong; Richard E Carson Journal: J Cereb Blood Flow Metab Date: 2007-05-09 Impact factor: 6.200
Authors: Friederike Vogel; Reinhard Gansmüller; Thomas Leiblein; Otto Dietmaier; Hans Wassmuth; Gerhard Gründer; Christoph Hiemke Journal: Eur Psychiatry Date: 2008-10-23 Impact factor: 5.361
Authors: C J Bench; A A Lammertsma; P M Grasby; R J Dolan; S J Warrington; M Boyce; K P Gunn; L Y Brannick; R S Frackowiak Journal: Psychopharmacology (Berl) Date: 1996-03 Impact factor: 4.530
Authors: Stephen M Stahl; Ashok Malla; John W Newcomer; Steven G Potkin; Peter J Weiden; Philip D Harvey; Antony Loebel; Eric Watsky; Cynthia O Siu; Steve Romano Journal: J Clin Psychopharmacol Date: 2010-08 Impact factor: 3.153
Authors: David Mamo; Shitij Kapur; C M Shammi; George Papatheodorou; Steve Mann; François Therrien; Gary Remington Journal: Am J Psychiatry Date: 2004-05 Impact factor: 18.112
Authors: Fernando Caravaggio; Gagan Fervaha; Yusuke Iwata; Eric Plitman; Jun Ku Chung; Shinichiro Nakajima; Wanna Mar; Philip Gerretsen; Julia Kim; M Mallar Chakravarty; Benoit Mulsant; Bruce Pollock; David Mamo; Gary Remington; Ariel Graff-Guerrero Journal: Int J Geriatr Psychiatry Date: 2017-11-07 Impact factor: 3.485